Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. - Klonoff,D.C.; Buse,J.B.; Nielsen,L.L. (Curr Med Res Opin, 2008)